Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
09 Jun 2022
09 Jun 2022
Historique:
received:
01
07
2021
accepted:
15
04
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Homologous repair deficiency (HRD) is present in many cancer types at variable prevalence and can indicate response to platinum-based chemotherapy and PARP inhibition. We developed a tumor classification system based on the loss of function of genes in the homologous recombination repair (HRR) pathway. To this end, somatic and germline alterations in BRCA1/2 and 140 other HRR genes were included and assessed for the impact on gene function. Additionally, information on the allelic hit type and on BRCA1 promoter hypermethylation was included. The HRDsum score including LOH, LST, and TAI was calculated for 8847 tumors of the TCGA cohort starting from genotyping data and for the subcohort of ovarian cancer also starting from WES data. Pan-cancer, deleterious BRCA1/2 alterations were detected in 4% of the tumors, while 18% of the tumors were HRD-positive (HRDsum ≥ 42). Across 33 cancer types, both BRCA1/2 alterations and HRD-positivity were most prevalent in ovarian cancer (20% and 69%). Pan-cancer, tumors with biallelic deleterious alterations in BRCA1/2 were separated strongly from tumors without relevant alterations (AUC = 0.89), while separation for tumors with monoallelic deleterious BRCA1/2 alterations was weak (AUC = 0.53). Tumors with biallelic deleterious alterations in other HHR genes were separated moderately from tumors without relevant alterations (AUC = 0.63), while separation for tumors with such monoallelic alterations was weaker (AUC = 0.57). In ovarian cancer, HRDsum scores calculated from WES data correlated strongly with HRDsum scores calculated from genotyping data (R = 0.87) and were slightly (4%) higher. We comprehensively analyzed HRD scores and their association with mutations in HRR genes in common cancer types. Our study identifies important parameters influencing HRD measurement and argues for an integration of HRDsum score with specific mutational profiles.
Identifiants
pubmed: 35681079
doi: 10.1038/s41698-022-00276-6
pii: 10.1038/s41698-022-00276-6
pmc: PMC9184602
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Informations de copyright
© 2022. The Author(s).
Références
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Hum Mutat. 2012 Jan;33(1):2-7
pubmed: 21990146
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
JCO Precis Oncol. 2020;4:442-465
pubmed: 32903788
JCO Precis Oncol. 2017 Nov;1:1-13
pubmed: 35172494
Hum Mutat. 2000;16(2):123-31
pubmed: 10923033
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Breast Cancer Res. 2014 May 15;16(3):R47
pubmed: 24887359
Nat Commun. 2020 Nov 4;11(1):5584
pubmed: 33149131
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
J Cancer Res Clin Oncol. 1996;122(3):135-40
pubmed: 8601560
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Hum Mutat. 2011 May;32(5):557-63
pubmed: 21520333
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
NPJ Breast Cancer. 2018 Jul 2;4:16
pubmed: 29978035
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
JCO Precis Oncol. 2018;2018:
pubmed: 30234181
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Cancer Discov. 2020 Dec;10(12):1808-1825
pubmed: 33139244
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530
pubmed: 29246904
Nat Rev Cancer. 2001 Nov;1(2):157-62
pubmed: 11905807
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Bioinformatics. 2005 Oct 15;21(20):3940-1
pubmed: 16096348
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Cancer Discov. 2012 Apr;2(4):366-375
pubmed: 22576213
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Clin Cancer Res. 2017 Aug 1;23(15):4086-4094
pubmed: 28223274
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
J Natl Cancer Inst. 2018 Jul 1;110(7):704-713
pubmed: 29788099
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Clin Cancer Res. 2019 Feb 1;25(3):1087-1097
pubmed: 30413523
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110